NSE: SUNPHARMA · 7 October 2026
- Sun Pharmaceutical Industries Ltd shares fell 1.28% to close at ₹1,781.0 on October 7, 2026. The stock moved within a day's range of ₹1,772.2 to ₹1,804.1 after opening at ₹1,793.6 with a gap-down of 0.58%.
- Sun Pharmaceutical Industries announced the creation of the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai, supported by a $2.5 million endowment. Dr. Mark G. Lebwohl was installed as the inaugural professor to fund academic leadership and research in dermatologic care. As a major player in US dermatology prescriptions, this initiative reinforces the company's long-term academic partnerships and brand presence.
- Trading volume was 0.77 times the 20-day average daily volume.
Why is Sun Pharmaceutical Ind L share price falling on 7 October 2026?
Sun Pharmaceutical Industries Ltd shares fell 1.28% to close at ₹1,781.0 on October 7, 2026. The stock moved within a day's range of ₹1,772.2 to ₹1,804.1 after opening at ₹1,793.6 with a gap-down of 0.58%.
The broader market also faced downward pressure, with the Nifty declining by 0.76% and the Nifty Pharma sector benchmark slipping 0.43%. Sun Pharma's price action ran slightly weaker than the sectoral trend. Over the preceding five trading days, the stock has retreated 1.96%, extending a 20-day return loss of 4.50%.
Company disclosures from October 6, 2026, highlighted that Sun Pharma established a $2.5 million endowed professorship in dermatology at the Icahn School of Medicine at Mount Sinai, directed by Dr. Mark G. Lebwohl. While this reflects ongoing specialty expansion and brand building in the US dermatology market, this corporate development is strategic in nature and provides long-term context rather than serving as a direct catalyst for today's intraday share price movement.
11.37 lakh shares traded by 7 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 14.77 lakh shares (0.77 times). The five-day average daily volume was 14.97 lakh shares. Separately, the NSE report for 6 October 2026 showed 8.86 lakh shares delivered, representing 59.93% of that day’s traded volume. The same report recorded 67,783 trades.
The 1.28% decline aligns with broader market and sectoral softening led by the Nifty's 0.76% drop. Trading volume remained below normal averages at 0.77% of the 20-day volume, alongside a total cash delivery volume of 885,883 shares representing a 59.93% delivery percentage, indicating no single confirmed operational catalyst drove the session.
Latest Company Developments
Sun Pharmaceutical Industries announced the creation of the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai, supported by a $2.5 million endowment. Dr. Mark G. Lebwohl was installed as the inaugural professor to fund academic leadership and research in dermatologic care. As a major player in US dermatology prescriptions, this initiative reinforces the company's long-term academic partnerships and brand presence.
It strengthens Sun Pharma's strategic positioning and institutional relationships within the North American specialty dermatology sector.
The company announced featured presentations at the European Academy of Dermatology and Venereology (EADV) Congress 2026 regarding LEQSELVI (deuruxolitinib). Data from an open-label extension study demonstrated sustained efficacy, durability of scalp hair regrowth, and a consistent safety profile over two years in adults with severe alopecia areata. These findings add to the clinical evidence supporting the company's high-growth global innovative medicines portfolio.
Demonstrating long-term safety and durable efficacy supports the commercial rollout and adoption of key specialty assets in regulated international markets.
Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care
'Completion and Result of Postal Ballot dated 25 August 2026'.
Receipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter Group.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 12.84% on 30 June 2026. This compares with 11.96% on 31 March 2026, a change of +0.88 percentage points.
The filing reported 49 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Progress and voting outcome of the ongoing Postal Ballot ending on October 31, 2026, concerning ESOP 2026 and enabling financial limits.
- Commercial update and prescription trends for LEQSELVI following long-term safety data presentations at the EADV Congress.
- Sectoral performance of the Nifty Pharma index and broader market direction.
- Delivery percentage trends against the 20-day average volume of 1,136,762 shares to gauge institutional participation.
Other Dated Coverage
More Sun Pharmaceutical Ind L news and dated analysis →
Frequently Asked Questions
What is the latest Sun Pharmaceutical Ind L company news?
Sun Pharmaceutical Industries announced the creation of the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai, supported by a $2.5 million endowment. Dr. Mark G. Lebwohl was installed as the inaugural professor to fund academic leadership and research in dermatologic care. As a major player in US dermatology prescriptions, this initiative reinforces the company's long-term academic partnerships and brand presence.
How strong was Sun Pharmaceutical Ind L’s trading volume?
11.37 lakh shares traded, 0.77 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.